PD-1、ICOS、4-1BB与食管癌的关系
The Relationship between PD-1, ICOS, 4-1BB, and Esophageal Cancer
摘要: 食管癌一直以来是我国最常见的肿瘤之一,而其诊断阶段是判定患者生存预后的关键。然而,大多数食管癌病例在晚期才被诊断出来,其治疗方案有限,生存率低。研究显示食管癌有许多相关的相关免疫因素,其中包括程序性死亡蛋白-1 (Programmed Death-1, PD-1)及其配体程序性蛋白死亡配体-1 (Programmed Death Ligand-1, PD-L1)呈现出显著的疾病相关性。此外,促进抗肿瘤T细胞功能的其他机制是T细胞表面表达的共刺激分子,如4-1BB、ICOS,它们可以诱导细胞因子的产生、抗凋亡分子的表达和免疫反应增强。本文探讨PD-1、ICOS、4-1BB与食管癌的联系,提供了新的思路来寻找改进食管癌的诊断和预后的生物标志物。
Abstract: Esophageal cancer has always been one of the most common tumors in China, and its diagnostic stage is the key to determining the survival prognosis of patients. However, most cases of esophage-al cancer are only diagnosed in the late stage, with limited treatment options and low survival rates. Studies have shown that esophageal cancer is associated with many immune factors, including Pro-grammed Death Protein-1 (PD-1) and its ligand Programmed Death Ligand-1 (PD-L1), which exhibit significant disease associations. In addition, other mechanisms that promote anti-tumor T cell func-tion are costimulatory molecules expressed on T cell surfaces, such as 4-1BB and ICOS, which can induce cytokine production, expression of anti-apoptotic molecules, and enhanced immune re-sponse. This article explores the relationship between PD-1, ICOS, 4-1BB and esophageal cancer, providing new ideas for finding biomarkers to improve the diagnosis and prognosis of esophageal cancer.
文章引用:阿尔曼·帕尔哈提, 王若峥. PD-1、ICOS、4-1BB与食管癌的关系[J]. 临床医学进展, 2024, 14(3): 632-637. https://doi.org/10.12677/ACM.2024.143749

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef
[3] Morgan, E., Soerjomataram, I., Rumgay, H., et al. (2022) The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortal-ity in 2020 and Projections to 2040: New Estimates from GLOBOCAN 2020. Gastroenterology, 163, 649-658.E2. [Google Scholar] [CrossRef] [PubMed]
[4] 杨欢, 孙宛怡, 王建炳, 等. 中国食管癌病因学、筛查及早期诊断研究进展[J]. 肿瘤防治研究, 2022, 49(3): 169-175.
[5] 王志鹏, 张海平, 宗亮, 等. 新疆地区食管癌发病风险的病例对照研究[J]. 中国肿瘤临床, 2017, 44(2): 92-95.
[6] Uhlenhopp, D.J., Then, E.O., Sunkara, T., et al. (2020) Epidemiology of Esophageal Cancer: Update in Global Trends, Etiology and Risk Factors. Clinical Journal of Gastroenterology, 13, 1010-1021. [Google Scholar] [CrossRef] [PubMed]
[7] Kakeji, Y., Oshikiri, T., Takiguchi, G., et al. (2021) Multimodal-ity Approaches to Control Esophageal Cancer: Development of Chemoradiotherapy, Chemotherapy, and Immunotherapy. Esophagus, 18, 25-32. [Google Scholar] [CrossRef] [PubMed]
[8] Obermannová, R., Alsina, M., Cervantes, A., et al. (2022) Oe-sophageal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 33, 992-1004. [Google Scholar] [CrossRef] [PubMed]
[9] Huang, T.X. and Fu, L. (2019) The Immune Land-scape of Esophageal Cancer. Cancer Communications, 39, Article No. 79. [Google Scholar] [CrossRef] [PubMed]
[10] Lin, E.W., Karakasheva, T.A., Hicks, P.D., et al. (2016) The Tu-mor Microenvironment in Esophageal Cancer. Oncogene, 35, 5337-5349. [Google Scholar] [CrossRef] [PubMed]
[11] Whiteside, T.L. (2008) The Tumor Microenvironment and Its Role in Promoting Tumor Growth. Oncogene, 27, 5904-5912. [Google Scholar] [CrossRef] [PubMed]
[12] Farhood, B., Najafi, M. and Mortezaee, K. (2019) CD8+ Cytotoxic T Lymphocytes in Cancer Immunotherapy: A Review. Journal of Cellular Physiology, 234, 8509-8521. [Google Scholar] [CrossRef] [PubMed]
[13] Zhou, N. and Hofstetter, W.L. (2020) Prognostic and Therapeutic Molecular Markers in the Clinical Management of Esophageal Cancer. Expert Review of Mo-lecular Diagnostics, 20, 401-411. [Google Scholar] [CrossRef] [PubMed]
[14] Choi, Y., Shi, Y., Haymaker, C.L., et al. (2020) T-Cell Ago-nists in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000966. [Google Scholar] [CrossRef] [PubMed]
[15] Campana, D., Schwarz, H. and Imai, C. (2014) 4-1BB Chimeric An-tigen Receptors. The Cancer Journal, 20, 134-140. [Google Scholar] [CrossRef
[16] Jin, X., Xu, Q., Pu, C., et al. (2021) Therapeutic Efficacy of Anti-CD19 CAR-T Cells in a Mouse Model of Systemic Lupus Erythematosus. Cellular & Molecular Immunology, 18, 1896-1903. [Google Scholar] [CrossRef] [PubMed]
[17] Panneton, V., Chang, J., Witalis, M., et al. (2019) Inducible T-Cell Co-Stimulator: Signaling Mechanisms in T Follicular Helper Cells and beyond. Immunological Reviews, 291, 91-103. [Google Scholar] [CrossRef] [PubMed]
[18] Solinas, C., Gu-Trantien, C. and Willard-Gallo, K. (2020) The Rationale behind Targeting the ICOS-ICOS Ligand Costimulatory Pathway in Cancer Immunotherapy. ESMO Open, 5, e000544. [Google Scholar] [CrossRef] [PubMed]
[19] Zou, L.Q., Yang, X., Li, Y.D. and Zhu, Z.F. (2019) Immune Checkpoint Inhibitors: A New Era for Esophageal Cancer. Expert Review of Anticancer Therapy, 19, 731-738. [Google Scholar] [CrossRef] [PubMed]
[20] Dhupar, R., Van Der Kraak, L., Pennathur, A., et al. (2017) Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor. The Annals of Thoracic Surgery, 103, 1340-1349. [Google Scholar] [CrossRef] [PubMed]
[21] O’Neill, R.E. and Cao, X. (2019) Co-Stimulatory and Co-Inhibitory Pathways in Cancer Immunotherapy. Advances in Cancer Research, 143, 145-194. [Google Scholar] [CrossRef] [PubMed]
[22] Xie, F., Xu, M., Lu, J., et al. (2019) The Role of Exosomal PD-L1 in Tumor Progression and Immunotherapy. Molecular Cancer, 18, Article No. 146. [Google Scholar] [CrossRef] [PubMed]
[23] Gubin, M.M., Zhang, X., Schuster, H., et al. (2014) Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens. Nature, 515, 577-581. [Google Scholar] [CrossRef] [PubMed]
[24] Guo, W., Wang, P., Li, N., et al. (2018) Prognostic Value of PD-L1 in Esophageal Squamous Cell Carcinoma: A Meta-Analysis. Oncotarget, 9, 13920-13933. [Google Scholar] [CrossRef] [PubMed]
[25] Okadome, K., Baba, Y., Nomoto, D., et al. (2020) Prognostic and Clinical Impact of PD-L2 and PD-L1 Expression in a Cohort of 437 Oesophageal Cancers. British Journal of Cancer, 122, 1535-1543. [Google Scholar] [CrossRef] [PubMed]
[26] Baba, Y., Yagi, T., Kosumi, K., et al. (2019) Morphological Lymphocytic Reaction, Patient Prognosis and PD-1 Expression after Surgical Resection for Oesophageal Cancer. British Journal of Surgery, 106, 1352-1361. [Google Scholar] [CrossRef] [PubMed]
[27] Amatore, F., Gorvel, L. and Olive, D. (2020) Role of Inducible Co-Stimulator (ICOS) in Cancer Immunotherapy. Expert Opinion on Biological Therapy, 20, 141-150. [Google Scholar] [CrossRef] [PubMed]
[28] Edwards, J., Tasker, A., Pires Da Silva, I., et al. (2019) Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets across Longitudinal Specimens in Treat-ment-Naïve Melanoma Patients: Implications for Clinical Trials. Clinical Cancer Research, 25, 3247-3258. [Google Scholar] [CrossRef
[29] Nagase, H., Takeoka, T., Urakawa, S., et al. (2017) ICOS+ Foxp3+ TILs in Gastric Cancer Are Prognostic Markers and Effector Regulatory T Cells Associated with Helicobacter Pylori. International Journal of Cancer, 140, 686-695. [Google Scholar] [CrossRef] [PubMed]
[30] Zappasodi, R., Sirard, C., Li, Y., et al. (2019) Rational Design of An-ti-GITR-Based Combination Immunotherapy. Nature Medicine, 25, 759-766. [Google Scholar] [CrossRef] [PubMed]
[31] Hong, M.H., Shin, S.J., Shin, S.K., et al. (2019) High CD3 and ICOS and Low TIM-3 Expression Predict Favourable Survival in Resected Oesophageal Squamous Cell Carcinoma. Scientific Reports, 9, Article No. 20197. [Google Scholar] [CrossRef] [PubMed]
[32] Chester, C., Sanmamed, M.F., Wang, J., et al. (2018) Immuno-therapy Targeting 4-1BB: Mechanistic Rationale, Clinical Results, and Future Strategies. Blood, 131, 49-57. [Google Scholar] [CrossRef] [PubMed]
[33] Wilcox, R, A., Tamada, K., Flies, D, B., et al. (2004) Ligation of CD137 Receptor Prevents and Reverses Established Anergy of CD8+ Cytolytic T Lymphocytes in Vivo. Blood, 103, 177-184. [Google Scholar] [CrossRef] [PubMed]
[34] Menk, A.V., Scharping, N.E., Rivadeneira, D.B., et al. (2018) 4-1BB Costimulation Induces T Cell Mitochondrial Function and Biogenesis Enabling Cancer Immunotherapeutic Responses. Journal of Experimental Medicine, 215, 1091-1100. [Google Scholar] [CrossRef] [PubMed]
[35] Williams, J.B., Horton, B.L., Zheng, Y., et al. (2017) The EGR2 Tar-gets LAG-3 and 4-1BB Describe and Regulate Dysfunctional Antigen-Specific CD8+ T Cells in the Tumor Microenvi-ronment. The Journal of Experimental Medicine, 214, 381-400. [Google Scholar] [CrossRef] [PubMed]
[36] Newcomb, E.W., et al. (2010) Radiotherapy Enhances Antitumor Effect of Anti-CD137 Therapy in a Mouse Glioma Model. Radiation Research, 173, 426-432.